Enhanced anti-tumor effects of HPV16E749-57-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150

Cancer Epidemiology

Volumn 37, Issue 2, 2013, Pages 172-178

  Chen, Shisheng ^a   Ou, Rongying ^a   Tang, Jun ^b   Deng, Xiufang ^a   Wu, Yuzhang ^c   van Velkinburgh, Jennifer C ^d   Ni, Bing ^c   Xu, Yunsheng ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b The 105th Hospital of PLA   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d Van Velkinburgh Initiative for Collaboratory BioMedical Research   (United States)

Author keywords

Adjuvant; Cytotoxic T cells; E749 57 peptide; Epitope; HPV16; Oxygen regulated protein 150; Polyinosinic:polycytidylic acid

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN; OXYGEN REGULATED PROTEIN 150; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN E7; WART VIRUS VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANIMALS; CANCER VACCINES; DISEASE MODELS, ANIMAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PEPTIDE FRAGMENTS; POLY I-C; PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINES, COMBINED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875809701     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.10.005     Document Type: Article

References (42)

1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2:342-350.
2. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
3. Trimble C.L., Frazer I.H. Development of therapeutic HPV vaccines. Lancet Oncol 2009, 10:975-980.
4. Peng S., Trimble C., Alvarez R.D., Huh W.K., Lin Z., Monie A., et al. Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Ther 2008, 15:1156-1166.
5. Welters M.J., Kenter G.G., Piersma S.J., Vloon A.P., Lowik M.J., Berends-van der Meer D.M., et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008, 14:178-187.
6. Lepique A.P., Rabachini T., Villa L.L. HPV vaccination: the beginning of the end of cervical cancer? A review. Mem Inst Oswaldo Cruz 2009, 104:1-10.
7. Ressing M.E., Sette A., Brandt R.M., Ruppert J., Wentworth P.A., Hartman M., et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995, 154:5934-5943.
8. Toes R.E., Offringa R., Blom R.J., Melief C.J., Kast W.M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 1996, 93:7855-7860.
9. Callahan M.K., Garg M., Srivastava P.K. Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation. Proc Natl Acad Sci USA 2008, 105:1662-1667.
10. Millar D.G., Garza K.M., Odermatt B., Elford A.R., Ono N., Li Z., et al. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat Med 2003, 9:1469-1476.
11. Singh-Jasuja H., Scherer H.U., Hilf N., Arnold-Schild D., Rammensee H.G., Toes R.E., et al. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol 2000, 30:2211-2215.
12. Beachy S.H., Kisailus A.J., Repasky E.A., Subjeck J.R., Wang X.Y., Kazim A.L. Engineering secretable forms of chaperones for immune modulation and vaccine development. Methods (San Diego, CA) 2007, 43:184-193.
13. Park J., Easton D.P., Chen X., MacDonald I.J., Wang X.Y., Subjeck J.R. The chaperoning properties of mouse grp170, a member of the third family of hsp70 related proteins. Biochemistry 2003, 42:14893-14902.
14. Kutomi G., Tamura Y., Okuya K., Yamamoto T., Hirohashi Y., Kamiguchi K., et al. Targeting to static endosome is required for efficient cross-presentation of endoplasmic reticulum-resident oxygen-regulated protein 150-peptide complexes. J Immunol 2009, 183:5861-5869.
15. Wang X.Y., Kazim L., Repasky E.A., Subjeck J.R. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J Immunol 2001, 166:490-497.
16. Wang X.Y., Kazim L., Repasky E.A., Subjeck J.R. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease. Int J Cancer 2003, 105:226-231.
17. Wang X.Y., Manjili M.H., Park J., Chen X., Repasky E., Subjeck J.R. Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins. Methods (San Diego, CA) 2004, 32:13-20.
18. Huo W., Ye J., Liu R., Chen J., Li Q. Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice. Vaccine 2010, 28:6333-6337.
19. Yuan B., Xian R., Wu X., Jing J., Chen K., Liu G., et al. Endoplasmic reticulum chaperone glucose regulated protein 170-Pokemon complexes elicit a robust antitumor immune response in vivo. Immunobiology 2012, 217:738-742.
20. Wang X.Y., Yi H., Yu X., Zuo D., Subjeck J.R. Enhancing antigen cross-presentation and T-cell priming by complexing protein antigen to recombinant large heat-shock protein. Methods Mol Biol (Clifton, NJ) 2011, 787:277-287.
21. Gao P., Sun X., Chen X., Subjeck J., Wang X.Y. Secretion of stress protein grp170 promotes immune-mediated inhibition of murine prostate tumor. Cancer Immunol Immunother 2009, 58:1319-1328.
22. Gao P., Sun X., Chen X., Wang Y., Foster B.A., Subjeck J., et al. Secretable chaperone Grp170 enhances therapeutic activity of a novel tumor suppressor, mda-7/IL-24. Cancer Res 2008, 68:3890-3898.
23. Binder R.J., Anderson K.M., Basu S., Srivastava P.K. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J Immunol 2000, 165:6029-6035.
24. Manjili M.H., Park J.E., Facciponte J.G., Wang X.Y., Subjeck J.R. Immunoadjuvant chaperone, GRP170, induces 'danger signals' upon interaction with dendritic cells. Immunol Cell Biol 2006, 84:203-208.
25. Cui Z., Qiu F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother 2006, 55:1267-1279.
26. Schulz O., Diebold S.S., Chen M., Naslund T.I., Nolte M.A., Alexopoulou L., et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005, 433:887-892.
27. Warger T., Osterloh P., Rechtsteiner G., Fassbender M., Heib V., Schmid B., et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006, 108:544-550.
28. Trumpfheller C., Caskey M., Nchinda G., Longhi M.P., Mizenina O., Huang Y., et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 2008, 105:2574-2579.
29. Longhi M.P., Trumpfheller C., Idoyaga J., Caskey M., Matos I., Kluger C., et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009, 206:1589-1602.
30. O'Neill L.A., Bryant C.E., Doyle S.L. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009, 61:177-197.
31. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996, 56:21-26.
32. Wulff S., Pries R., Wollenberg B. Cytokine release of human NK cells solely triggered with Poly I:C. Cell Immunol 2010, 263:135-137.
33. Salem M.L., El-Naggar S.A., Kadima A., Gillanders W.E., Cole D.J. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 2006, 24:5119-5132.
34. van der Burg S.H., Melief C.J. Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol 2011, 13:13.
35. Wu C.Y., Monie A., Pang X., Hung C.F., Wu T.C. Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. J Biomed Sci 2010, 17:88.
36. Ren F., Xu Y., Mao L., Ou R., Ding Z., Zhang X., et al. Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice. Cancer Biol Ther 2010, 9:134-141.
37. Palucka K., Ueno H., Fay J., Banchereau J. Dendritic cells and immunity against cancer. J Intern Med 2011, 269:64-73.
38. Palucka K., Banchereau J., Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010, 33:464-478.
39. Mescher M.F., Curtsinger J.M., Agarwal P., Casey K.A., Gerner M., Hammerbeck C.D., et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 2006, 211:81-92.
40. Sioud M. Overcoming self-tolerance to tumour cells. Methods Mol Biol (Clifton, NJ) 2010, 629:495-505.
41. Ahonen C.L., Doxsee C.L., McGurran S.M., Riter T.R., Wade W.F., Barth R.J., et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004, 199:775-784.
42. Hartman Z.C., Osada T., Glass O., Yang X.Y., Lei G.J., Lyerly H.K., et al. Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Research 2010, 70:7209-7220.